These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28751663)

  • 21. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
    Mathews M; Gopal S; Singh A; Nuamah I; Pungor K; Tan W; Soares B; Kim E; Savitz AJ
    Neuropsychiatr Dis Treat; 2020; 16():1533-1542. PubMed ID: 32606705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
    Nash AI; Turkoz I; Savitz AJ; Mathews M; Kim E
    Neuropsychiatr Dis Treat; 2019; 15():731-737. PubMed ID: 30962688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.
    Zhang F; Si T; Chiou CF; Harris AW; Kim CY; Jahagirdar P; Ascher S
    Neuropsychiatr Dis Treat; 2015; 11():657-68. PubMed ID: 25792835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis.
    Patel C; Khoury AE; Huang A; Wang L; Bashyal R
    Curr Ther Res Clin Exp; 2020; 92():100587. PubMed ID: 32714469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia.
    Pungor K; Sanchez P; Pappa S; Attal J; Leopold K; Steegen G; Vita A; Marsella C; Verrijcken C; Lahaye M; Wooller A
    BMC Psychiatry; 2021 Jun; 21(1):300. PubMed ID: 34107886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
    O'Donnell A; Rao S; Turkoz I; Gopal S; Kim E
    Neuropsychiatr Dis Treat; 2021; 17():1-9. PubMed ID: 33442251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
    Patel C; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Tandon N; El Khoury AC
    Drugs Real World Outcomes; 2020 Mar; 7(1):19-29. PubMed ID: 31786737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.
    Brasso C; Bellino S; Bozzatello P; Montemagni C; Rocca P
    Neuropsychiatr Dis Treat; 2017; 13():2767-2779. PubMed ID: 29158676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.
    Kern Sliwa J; Savitz A; Nuamah I; Mathews M; Gopal S; Elefant E; Najarian D; Alphs L
    Perspect Psychiatr Care; 2018 Oct; 54(4):530-538. PubMed ID: 29446084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.
    Zhao J; Li L; Shi J; Li Y; Xu X; Li K; Zhang L; Cai S; Feng Y; Zhuo J; Liu W; Lu H
    Neuropsychiatr Dis Treat; 2017; 13():2045-2056. PubMed ID: 28814873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients', Relatives', and Mental Health Professionals' Perspectives.
    Spoelstra SK; Bruins J; Bais L; Seerden P; Castelein S; Knegtering H
    Patient Prefer Adherence; 2022; 16():615-624. PubMed ID: 35283623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
    Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
    Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
    Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal.
    García-Carmona JA; Pappa S
    Drug Healthc Patient Saf; 2023; 15():113-123. PubMed ID: 37720806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.